Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Triosephosphate isomerase (TIM) from Trypanosoma cruzi (TcTIM) is a crucial enzyme in the glycolytic pathway of this protozoan parasite, which causes Chagas disease. It catalyzes the reversible interconversion between dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (GAP). TcTIM is considered an essential enzyme for parasite survival and has been validated as a promising drug target for anti-Chagas therapies. Inhibitors targeting TcTIM have shown potent trypanosomicidal activity with minimal toxicity toward mammalian cells due to structural differences. Inhibition leads to disruption of glycolysis and accumulation of toxic metabolites, ultimately impairing parasite viability.
Inhibition of triosephosphate isomerase, disruption of glycolysis, accumulation of methylglyoxal and advanced glycation end products.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Triosephosphate Isomerase (Trypanosoma cruzi).